Efficacy of Favipiravir in treatment of mild & moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Infectious Diseases"
DOI: 10.1016/j.ijid.2021.12.109
Abstract: Purpose To study tolerability and outcome of oral favipiravir treatment among COVID-19 patients in Nepal. Methods & Materials In this multi-centered randomized, open-labelled phase III clinical trial, we enrolled 18-80 years old, RT-PCR confirmed patients… read more here.
Keywords: randomized open; labelled phase; infection; mild moderate ... See more keywords
MO392ACUTE KIDNEY INJURY IN HOSPITALIZED PATIENTS WITH COVID-19: A SINGLE-CENTER EXPERIENCE
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfab082.0046
Abstract: Abstract Background and Aims Preliminary reports indicate that AKI (acute kidney injury) seem to be associated with coronavirus disease 2019 (COVID-19) severity and outcomes. Although the reported incidence of AKI among hospitalized patients with COVID-19… read more here.
Keywords: kidney injury; treatment; favipiravir treatment; patients covid ... See more keywords
Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of infection in developing countries"
DOI: 10.3855/jidc.14033
Abstract: INTRODUCTION Early experience with favipiravir in the treatment of COVID-19 is promising, but no clinical data have been published in medical journals. This study aimed to review the experience with favipiravir treatment for COVID-19 pneumonia… read more here.
Keywords: response; treatment; pneumonia; favipiravir treatment ... See more keywords